The FGF21 analogue LY2405319 was subcutaneously administered for 28 days to patients with obesity and T2DM, resulting in attenuated dyslipidaemia, reduced body weight and plasma insulin, and increased adiponectin levels [94]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.